Roche CEO Brushes Off Currency Headwinds While Ramping Up U.S. Expansion

Roche CEO Brushes Off Currency Headwinds While Ramping Up U.S. Expansion

The Swiss pharmaceutical giant Roche saw its first-quarter revenues decline as currency fluctuations and intensifying generic drug competition took their toll on the company's financial performance.

Roche's first-quarter sales totaled 14.7 billion Swiss francs ($18.7 billion), representing a 5% decrease year-over-year. However, when adjusted for currency variations, the figure rose 6% on a constant currency basis, the company disclosed.

Currency Impact Masks Underlying Growth

The substantial appreciation of the Swiss franc relative to major currencies, particularly against the U.S. dollar, significantly distorted the reported results when expressed in Swiss francs compared to constant exchange rates. The Swiss franc strengthened 12% against the U.S. dollar throughout 2025 and has continued its upward trajectory, gaining an additional 1% so far this year.

Chief Executive Officer Thomas Schinecker sought to reframe the quarterly earnings narrative, emphasizing that results depend largely on how one interprets the data. He highlighted that when measured in U.S. dollars, sales actually increased 9% during the quarter.

"We spend most of our money in the U.S., and we have most our debt in the U.S., we've just recently bought another company in the U.S. We will continue to invest in the U.S., and we don't see that as a major issue," Schinecker remarked during an appearance on Squawk Box Europe.

Patent Cliff Looms as Industry Faces Generic Challenge

Europe's leading pharmaceutical manufacturers are confronting mounting pressure as the sector braces for a wave of patent expirations approaching the decade's end, when older medications will encounter generic competitors. This phenomenon, commonly referred to as the "patent cliff," threatens revenue streams across the industry.

Weight-Loss Market Ambitions

Roche is positioning itself as a formidable contender in the rapidly expanding weight-loss pharmaceutical sector. The company is pursuing an ambitious strategy to capture significant market share with its investigational medication CT-388, aiming to establish itself among the top three players alongside current market leaders Novo Nordisk and Eli Lilly.

In statements made to German publication Handelsblatt earlier this week, Schinecker disclosed that Roche is targeting a double-digit market share in the weight-loss medications category.